Clinical Trial Details
— Status: Recruiting
Administrative data
NCT number |
NCT05958524 |
Other study ID # |
2023-49 |
Secondary ID |
|
Status |
Recruiting |
Phase |
|
First received |
|
Last updated |
|
Start date |
December 15, 2022 |
Est. completion date |
November 1, 2023 |
Study information
Verified date |
August 2023 |
Source |
The Second Affiliated Hospital of Chongqing Medical University |
Contact |
Xian Yu, professor |
Phone |
18512356862 |
Email |
1clinicaltrial[@]hospital.cqmu.edu.cn |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational
|
Clinical Trial Summary
1. Preliminarily explore the correlation factors of differences in the efficacy of
levamlodipine besylate in the treatment of hypertension.
2. Quantitatively analyze the influence of covariates such as patient demographic factors,
personal history, combined medications, and biochemical indicators on the efficacy of
levamlodipine besylate, and establish a population pharmacokinetic model of
levamlodipine besylate, to achieve clinical Individualized treatment and rational drug
use.
Description:
This study is a retrospective study, which intends to collect and extract relevant
information from outpatient medical records from the information center of our hospital, and
evaluate the difference in the efficacy of antihypertensive treatment with levamlodipine
besylate in newly diagnosed hypertensive patients in our hospital; After antihypertensive
treatment with levamlodipine besylate, the correlation analysis was carried out on the
influencing factors of blood pressure control in the follow-up, and the covariates such as
demographic factors, personal history, combined medications, and biochemical indicators were
initially explored. The curative effect of dipine.
Through the population pharmacokinetic modeling method of quantitative pharmacology, the
influence of covariates such as demographic factors, personal history, combined medication,
and biochemical indicators on the curative effect of levamlodipine besylate was
quantitatively explored. The population pharmacokinetic model of levamlodipine besylate was
established in order to provide reference for clinical individualized treatment and rational
drug use.